Kaplan Fox Alerts Fractyl Health, Inc. (GUTS) Investors to a Securities Class Action Deadline on October 20, 2026 Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - August 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl Health" or the "Company") (NASDAQ: GUTS) on behalf of investors that purchased or otherwise acquired Fractyl Health securities between January 13, 2025 and January 29, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Fractyl Health and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 20, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
According to the complaint, on January 29, 2026, during pre-market hours, Fractyl issued a press release announcing six-month data from the REMAIN-1 Midpoint Cohort. The press release disclosed, in relevant part, that "[a]cross the prespecified efficacy population . . . , Revita-treated patients experienced a 4.5% weight regain vs 7.5% in the sham arm at 6 months", representing a significantly more modest efficacy result than previously disclosed results and falling short of investor expectations, while stating that "[t]he Midpoint Cohort was not designed to be sufficiently powered for efficacy analysis[.]"
The same day, also during pre-market hours, the complaint alleges Fractyl hosted a conference call and that during the call, Fractyl's CEO indicated that issues at one of the REMAIN-1 Midpoint Cohort study sites, which "had higher-than-expected regain across both arms," were at least partly to blame for the cohort's disappointing six-month efficacy results.
Following these disclosures, Fractyl's stock price fell $1.25 per share, or 68%, to close at $0.58 per share on January 29, 2026.
The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort's clinical sites compromised the integrity of its efficacy results; and (ii) accordingly, Revita's clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess Revita's efficacy.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/fractyl-health-inc-class-action-lawsuit-learn-more-now/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311413
Source: Kaplan Fox & Kilsheimer LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Kaplan Fox & Kilsheimer LLP or all companies in the Legal industry.
Kaplan Fox Alerts Fractyl Health, Inc. (GUTS) Investors to a Securities Class Action Deadline on October 20, 2026
2026-08-25 11:30 AM EDT
Kaplan Fox Urges Investors of GoDaddy Inc. (GDDY) with Significant Losses to Seek a Leadership Role Before October 20, 2026
2026-08-24 3:45 PM EDT
Kaplan Fox Encourages Alignment Healthcare, Inc. (ALHC) Investors Who Suffered Losses to Learn About Their Legal Rights
2026-08-24 3:30 PM EDT
Jan 30, 2026
To understand where public relations and investor communications are headed, we analyzed over 39,000 press releases distributed in 2025. The data is clear: success now depends on a careful balance between AI-readability and human trust. More than 50% of news activity on the TMX Newsfile network is now driven by AI bots from OpenAI and Microsoft. Yet these systems rely on human-verified facts to ground their answers. We have entered a “ zero-click ” reality, where Generative AI systems...
Litigation and Regulation
Legal